Literature DB >> 15254938

Visual hallucination in Parkinson's disease with FDG PET.

Atsuko Nagano-Saito1,2, Yukihiko Washimi2, Yutaka Arahata1,2, Katsushige Iwai2, Shoji Kawatsu1, Kengo Ito1, Akinori Nakamura1, Yuji Abe2, Takako Yamada2, Takashi Kato1, Teruhiko Kachi2.   

Abstract

To determine the characteristics of cerebral glucose metabolism in Parkinson's disease patients with visual hallucinations, group comparison studies using [18F]fluorodeoxyglucose positron emission tomography were performed. Nondemented Parkinson's disease patients in advanced stages were classified into two groups: (1) patients without visual hallucinations; (2) patients with visual hallucinations. Compared to patients without hallucinations, the relative regional cerebral glucose metabolic rate was greater in the frontal areas in patients with visual hallucinations, and the increase reached a significant level in the left superior frontal gyrus. Relative frontal hypermetabolism may be a feature of Parkinson's disease patients with visual hallucinations. Copyright 2004 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254938     DOI: 10.1002/mds.20129

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  21 in total

Review 1.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

2.  New insights into the organization of the basal ganglia.

Authors:  James B Koprich; Tom H Johnston; Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

Review 3.  Visual hallucinations and the Charles Bonnet syndrome.

Authors:  Dominic H Ffytche
Journal:  Curr Psychiatry Rep       Date:  2005-06       Impact factor: 5.285

Review 4.  Interaction Between Neuropsychiatric Symptoms and Cognitive Performance in Parkinson's Disease: What Do Clinical and Neuroimaging Studies Tell Us?

Authors:  Alexandru Hanganu; Oury Monchi
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-15       Impact factor: 5.081

5.  Positron emission tomography neuroimaging in Parkinson's disease.

Authors:  Clare Loane; Marios Politis
Journal:  Am J Transl Res       Date:  2011-07-10       Impact factor: 4.060

Review 6.  Hallucinations in Parkinson disease.

Authors:  Nico J Diederich; Gilles Fénelon; Glenn Stebbins; Christopher G Goetz
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

7.  Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment.

Authors:  Carmen Gasca-Salas; Pedro Clavero; David García-García; José A Obeso; María C Rodríguez-Oroz
Journal:  Hum Brain Mapp       Date:  2015-12-14       Impact factor: 5.038

Review 8.  Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Authors:  Anna Chang; Susan H Fox
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

Review 9.  The psychosis spectrum in Parkinson disease.

Authors:  Dominic H Ffytche; Byron Creese; Marios Politis; K Ray Chaudhuri; Daniel Weintraub; Clive Ballard; Dag Aarsland
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

Review 10.  Neuroimaging in Parkinson disease: from research setting to clinical practice.

Authors:  Marios Politis
Journal:  Nat Rev Neurol       Date:  2014-11-11       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.